NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment

Reuters2026/08/10 12:31

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NanoViricides won ACOREP clearance in DR Congo to launch a Phase II trial of NV-387 oral gummies for Bundibugyo ebolavirus.
Om Sai Clinical Research was hired as CRO; drug supply for trial start is already in-country.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608100830ACCESSWRNAPR_____1205313) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment

You may also like

Crypto prices